Sign inJoin waitlistJoin the waitlist

Lisa McGregor

Clinical Director, Pediatric Hematology/Oncology · Penn State Milton S Hershey Medical Center

Credentials: · · · · · ·

History

Pediatric Hematology/Oncology · Penn State Milton S Hershey Medical Center
Present
Penn State Milton S Hershey Medical Center
Present

Pediatric Hematology Oncology
St Jude Children's Research Hospital
2001–2004
General Academic Duke University School of Medicine
1998–2001
Johns Hopkins Univ Sch of Med
1994–1998

Research

Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma
Journal of Clinical Oncology · 2014 · 132 citations
Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression
Proceedings of the National Academy of Sciences of the United States of America · 1999 · First of 9 authors · 125 citations
UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan
Journal of Clinical Oncology · 2007 · Last of 12 authors · 81 citations

Wayne Furman
19 papers
Victor Santana
17 papers
Andrew Davidoff
13 papers
SS
Sheri Spunt
7 papers
Matthew Krasin
6 papers
Fariba Navid
5 papers
Carlos Rodriguez-Galindo
4 papers
Pooja Rao
4 papers
Atman Pai
3 papers
Jeffrey Dome
3 papers
Najat Daw
3 papers
Raul Ribeiro
3 papers

Clinical trials

ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors
Principal investigator · Completed · Phase 1
St. Jude Children's Research Hospital
2005–2011
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Principal investigator · Terminated · Phase 1
National Cancer Institute (NCI)
2004
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030